Pharma News

(28th Apr, 2014); In their last meeting, Drugs Technical Advisory Board (DTAB) raised the issue of wide variation in the quality of generic drugs manufactured in the country by small scale sector. The generic medicines of lower quality have not been found effective in patients.

(28th April, 2014); Strides Arcolab announced on 25th April that its Oral Dosage Forms  manufacturing site (KRS Gardens) in Bangalore was recently inspected by the USFDA as part of  GMP compliance audit and the facility continues to be approved.

(24th Apr, 2014); Now Novartis will focus more on oncology business, GlaxoSmithKline will focus on vaccines business and Lilly to concentrate more on Animal Health Division, concluded from portfolio transformation deals between said companies.

Shiseido Co., Ltd. announces plans to open the Shiseido Cell-Processing and Expansion Center (SPEC) on May 1, 2014. The center, located in the in the Kobe Biomedical Innovation Cluster in Kobe, Japan, will centralize research and development on hair regenerative medicine with an aim toward commercialization.

Indian Council of Medical research (ICMR) releases consensus document for management of esophageal cancer (EC), prepared as an outcome of ICMR Subcommittee on EC.

The U.S. Food and Drug Administration approved Tanzeum (albiglutide), manufactured by GlaxoSmithKline, subcutaneous injection to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes.

Team of scientists, from University of Edinburgh, have succeeded in regenerating a living organ for the first time. Living mouse organ is regenerated successfully and transplanted in to a mouse. Regenerated organ closely resembles the juvenile thymus in terms of architecture and gene expression profile.

Ranbaxy saw some good news from the US drug regulator just days before the announcement of its acquisition by Sun Pharmaceutical in a $4-billion deal inclusive of debt.

New studies escalate medical concerns about glioma (a malignant brain tumor) from cell phone use. The BioInitiative Working Group (BWG) noted that evidence for health risk from wireless technology is growing stronger and require immediate action. The Group released a mid-year update covering new science studies from 2012 to 2014.